https://mindmedicinelaw.com/briefing/psilocybin-mdma-and-memory-new-findings-and-implications-20260723-25425The Psychedelic Journalen2026-07-24T15:05:30.698096+00:00Psilocybin, MDMA and Memory: New Findings and Implicationspsilocybin, MDMA, working memory, neurophysiological activity, clinical trials, psychedelic research, cognitive safety, mental health treatmenthttps://mindmedicinelaw.com/briefing/dea-seeks-comments-on-form-222-extension-impact-on-psychedelics-20260723-24980The Psychedelic Journalen2026-07-23T15:06:55.934795+00:00DEA Seeks Comments on Form 222 Extension: Impact on PsychedelicsDEA Form 222, controlled substances, psychedelic research, regulatory compliance, Schedules I and II, drug enforcement, supply chain, legal framework, public comments, Paperwork Reduction Acthttps://mindmedicinelaw.com/briefing/epa-s-proposed-snurs-impact-on-psychedelic-chemical-substances-20260723-24977The Psychedelic Journalen2026-07-23T15:06:41.987724+00:00EPA's Proposed SNURs: Impact on Psychedelic Chemical SubstancesEPA SNURs, Toxic Substances Control Act, chemical substances regulation, psychedelic research, regulatory compliance, manufacturing and processing, chemical evaluation, industry impact, regulatory delays, TSCA ruleshttps://mindmedicinelaw.com/briefing/fda-s-cmc-strategy-for-accelerated-psychedelic-therapies-20260723-24951The Psychedelic Journalen2026-07-23T15:06:29.824905+00:00FDA's CMC Strategy for Accelerated Psychedelic TherapiesFDA strategy, CMC readiness, psychedelic therapies, accelerated clinical development, PDUFA VII, drug manufacturing, regulatory approval, mental health treatments, product quality, clinical trialshttps://mindmedicinelaw.com/briefing/psycholytic-therapy-historical-insights-for-modern-psychedelic-research-20260722-25195The Psychedelic Journalen2026-07-23T22:06:34.839150+00:00Psycholytic Therapy: Historical Insights for Modern Psychedelic Researchpsycholytic therapy, psychedelic-assisted psychotherapy, LSD, therapeutic alliance, set and setting, clinical trials, historical review, psychedelic research, psychotherapy, therapeutic frameworkshttps://mindmedicinelaw.com/briefing/virtual-reality-s-role-in-transformative-experiences-20260722-25193The Psychedelic Journalen2026-07-23T22:06:24.152587+00:00Virtual Reality's Role in Transformative Experiencesvirtual reality, transformative experiences, epistemic expansion, positive emotions, mental health, therapeutic interventions, psychological well-being, VR technology, personal growth, clinical applicationshttps://mindmedicinelaw.com/briefing/advancing-treatment-resistant-depression-research-20260722-25204The Psychedelic Journalen2026-07-23T22:06:16.217752+00:00Advancing Treatment-Resistant Depression Researchtreatment-resistant depression, TRD research, staging in depression, measurement-based care, pharmacological interventions, demographic-specific burden, neuromodulation, depression subtypes, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/magnesium-ibogaine-in-tbi-treatment-emerging-insights-20260722-25194The Psychedelic Journalen2026-07-23T22:06:00.143240+00:00Magnesium-Ibogaine in TBI Treatment: Emerging Insightsmagnesium-ibogaine, traumatic brain injury, post-traumatic stress disorder, default mode network, mystical experiences, psychedelic-assisted treatment, veterans, clinical trials, neuroscience, mental healthhttps://mindmedicinelaw.com/briefing/ketamine-therapy-for-grief-related-depression-a-new-frontier-20260722-24935The Psychedelic Journalen2026-07-23T15:07:25.127233+00:00Ketamine Therapy for Grief-Related Depression: A New Frontierketamine therapy, grief-related depression, psychedelic-assisted therapy, mental health treatment, clinical trials, Pacific Mind Health, FDA approval, psychedelic research, treatment-resistant depression, psychedelic markethttps://mindmedicinelaw.com/briefing/fda-s-regulatory-framework-for-psychedelics-in-the-us-20260722-24934The Psychedelic Journalen2026-07-23T15:07:11.733016+00:00FDA's Regulatory Framework for Psychedelics in the USFDA psychedelic regulation, psychedelic medicine, clinical trials, psilocybin, MDMA, mental health treatment, drug approval process, therapeutic benefits, market dynamics, patient carehttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-epilepsy-therapeutic-potential-and-challenges-20260721-24931The Psychedelic Journalen2026-07-23T22:06:46.174569+00:00Psilocybin's Role in Epilepsy: Therapeutic Potential and Challengespsilocybin therapy, epilepsy treatment, serotonergic therapy, clinical trials, neuroplasticity, psychedelic research, FDA regulations, neurological disorders, psychoactive effects, drug interactionshttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-decision-making-in-uncertain-contexts-20260721-25156The Psychedelic Journalen2026-07-23T22:06:07.714146+00:00Psilocybin's Impact on Decision-Making in Uncertain Contextspsilocybin, decision-making, psychiatric disorders, neural mechanisms, reinforcement learning, clinical applications, positive outcomes, uncertainty, therapeutic use, risk assessmenthttps://mindmedicinelaw.com/briefing/new-framework-for-multi-scale-disease-progression-20260721-24858The Psychedelic Journalen2026-07-23T15:07:34.773571+00:00New Framework for Multi-Scale Disease Progressionmulti-scale disease progression, compound race pathology, friction-theoretic framework, chronic disease treatment, Metabolic Control Analysis, multi-system dysregulation, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/es-ketamine-s-role-in-functional-neurological-disorder-20260720-24813The Psychedelic Journalen2026-07-24T15:06:01.870278+00:00(Es)ketamine's Role in Functional Neurological Disorderesketamine, functional neurological disorder, systematic review, clinical trials, neuropsychiatric treatment, adverse effects, treatment efficacy, FND symptoms, psychiatric improvement, controlled trialshttps://mindmedicinelaw.com/briefing/esketamine-s-impact-on-anhedonia-insights-from-recent-rct-20260720-24863The Psychedelic Journalen2026-07-24T15:05:52.890192+00:00Esketamine's Impact on Anhedonia: Insights from Recent RCTesketamine, anhedonia, randomized controlled trial, psychiatric disorders, NMDA receptor, treatment-resistant depression, peer review, clinical validation, psychedelic research, therapeutic potentialhttps://mindmedicinelaw.com/briefing/blood-nfl-as-a-biomarker-in-neuro-trials-promise-and-challenges-20260720-24870The Psychedelic Journalen2026-07-24T15:05:43.176752+00:00Blood NfL as a Biomarker in Neuro Trials: Promise and Challengesneurofilament light chain, biomarker, neurodegenerative diseases, clinical trials, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, surrogate endpoint, treatment response, axonal injuryhttps://mindmedicinelaw.com/briefing/nested-boundary-model-psychedelic-impact-on-mind-states-20260719-25162The Psychedelic Journalen2026-07-24T15:06:18.293669+00:00Nested-Boundary Model: Psychedelic Impact on Mind Statesnested-boundary model, psychedelic risk profiles, Markov blankets, analytic idealism, psychological states, neuroscience research, clinical trials, boundary permeability, integrative coherence, mental healthhttps://mindmedicinelaw.com/briefing/neurobiology-of-trauma-implications-for-ptsd-treatment-20260717-24818The Psychedelic Journalen2026-07-24T15:06:29.282379+00:00Neurobiology of Trauma: Implications for PTSD TreatmentPTSD, neurobiology, amygdala hyperreactivity, HPA axis dysregulation, trauma-informed care, clinical practice, autonomic dysregulation, hypocortisolism, evidence-based interventions, mental health policy